News Search Results
May 08, 2025, 10:01 ET Al in Pathology Market worth $347.4 million by 2030 with 26.5% CAGR | MarketsandMarkets™
share of the market. This segment is also expected to grow at the highest CAGR during the forecast period. The increasing pharmaceutical & biotechnology R&D expenditure, the growth in high-throughput screening & imaging, the rising use of AI algorithms in pathology image analysis for the
More news about: MarketsandMarkets
May 08, 2025, 10:01 ET Agritech Market to Reach $8,150.15 million by 2024 in the short term and $34,831.17 Million by 2034 Globally, at 15.3% CAGR: Allied Market Research
market in the region, driven by substantial investments in agricultural technology, including advancements in precision farming, automation, and biotechnology. For instance, in February 2025, Pivot Bio launched its CERT-N, a new product designed for U.S. cotton crops. This
More news about: Allied Market Research
May 08, 2025, 09:30 ET Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic
More news about: Kytopen
May 08, 2025, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
SessionDate/Time: May 15, 5:30 p.m. CT ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
May 08, 2025, 07:00 ET Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL-22 for IBD in Digestive Diseases and Sciences Publication
Denmark, May 8, 2025 /PRNewswire/ -- Cytoki Pharma ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness interleukin-22 (IL-22) biology to drive improved metabolic and other health outcomes, today
More news about: Cytoki Pharma
May 08, 2025, 07:00 ET Avista Therapeutics Presents In Vivo Data for its AAV Capsid in Inherited Retinal Diseases at Association for Research in Vision and Ophthalmology 2025 Annual Meeting
Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today held an oral presentation on data showcasing progress towards
More news about: Avista Therapeutics
May 08, 2025, 07:00 ET Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale
drug candidates with unprecedented speed and efficiency, at scale, without sacrificing quality." About Peptone Peptone is a biotechnology company developing novel first-in-class small molecule therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases through
More news about: Peptone
May 08, 2025, 06:59 ET Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial
More news about: Q32 Bio
May 08, 2025, 06:45 ET Lilly announces transitions in executive leadership
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 08, 2025, 06:00 ET Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer
Mass., May 8, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, today announced that the first patient has been dosed in its STARt-002 clinical
More news about: Marengo Therapeutics
May 08, 2025, 05:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: Gross Law Firm
May 07, 2025, 21:00 ET SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
May 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase
More news about: SCG Cell Therapy Pte Ltd
May 07, 2025, 20:10 ET Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public
More news about: Brii Biosciences Limited
May 07, 2025, 20:10 ET 騰盛博藥在2025年EASL大會上公布了其正在進行的ENSURE 2期研究的最新突破數據，表明BRII-179在促進更高的HBsAg清除方面的作用
Elebsiran是一種經皮下注射給藥的靶向乙型肝炎病毒（HBV）的小干擾核糖核酸（siRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。 關於騰盛博藥 騰盛博藥（股票代碼：2137.HK）是一家生物技術公司，致力於針對存在巨大未被滿足的患者需求、治療手段有限，以及給患者帶來嚴重社會歧視的重大公共衛生挑戰開發
More news about: 騰盛博藥生物科技有限公司
May 07, 2025, 18:26 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
May 07, 2025, 16:30 ET Corteva Delivers Strong 1Q 2025, Reaffirms 2025 Outlook
commercialize Corteva's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v)
More news about: Corteva Agriscience
May 07, 2025, 14:53 ET AusperBio Presents Interim Phase IIb AHB-137 Clinical Data in a Late-Breaking Abstract at EASL™ Congress 2025
2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from its ongoing Phase IIb trial of AHB-137 in a late-breaking
More news about: AusperBio Therapeutics Inc.
May 07, 2025, 13:15 ET WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering
More news about: WallachBeth Capital LLC
May 07, 2025, 12:00 ET Apertura Gene Therapy Showcases the Progress of its Novel Human Transferrin Receptor AAV Capsid, TfR1 CapX, and Preclinical Programs for Tuberous Sclerosis Complex (TSC) at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
NEW YORK, May 7, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, will showcase significant regulatory, preclinical, and CMC advancements across several oral
More news about: Apertura Gene Therapy
May 07, 2025, 11:50 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
May 07, 2025, 11:02 ET GenoFAB Announces Publication of Groundbreaking Self-Documenting Plasmid Technology In Trends In Biotechnology
Self-Documenting Plasmids has been published in Trends in Biotechnology, introducing a breakthrough technology that could redefine the way plasmids are tracked, verified, and shared in the biotechnology industry. Developed by researchers at Colorado
More news about: GenoFAB
May 07, 2025, 10:30 ET Single Cell Analysis Market worth US$7.56 billion by 2030 with 14.7% CAGR | MarketsandMarkets™
technological developments in single-cell analysis products, the growing focus on the advancement of stem cell research, and the increasing focus on the biotechnology sector. However, the high cost of single-cell analysis products may hamper the growth of the market.
More news about: MarketsandMarkets
May 07, 2025, 10:25 ET INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the
More news about: Faruqi & Faruqi, LLP
May 07, 2025, 10:15 ET Hollow Fiber Ultrafiltration Market worth $4.85 billion by 2030 - Exclusive Report by MarketsandMarkets™
eliminate bacteria, viruses, and suspended solids without the use of chemicals, hollow fiber ultrafiltration systems are preferred. The growth of the biotechnology, food & beverage, and pharmaceutical sectors—all of which depend on sterile filtration—also contributes to market expansion. The global adoption
More news about: MarketsandMarkets
May 07, 2025, 10:00 ET Eurofins Viracor Revolutionizes Respiratory Diagnostics with New BAL Specimen Type for NeXGen® Fungal / AFB NGS Assay
technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions. Shares in Eurofins Scientific SE are listed on the Euronext
More news about: Viracor Eurofins